Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBC
Ruta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.
Sacituzumab Shows Consistent PFS and OS Benefit in mTNBC
Ruta D. Rao, MD, discussed the trial design and final efficacy results of the ASCENT trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer.